Emami Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/me9vf5rfc6xrccu06ah9lpne.pdf

Key Takeaways


Demand & Channel Dynamics

Mohan Goenka: "We are well prepared. We are well geared, but very difficult to say when the market would bounce back."

Brand Portfolio Health

Brand / SegmentTrendCommentary
Navratna & Dermi Cool▲ 12% growthUrban and premium demand holding up well; core growth driver in the domestic portfolio.
Healthcare (Zandu)▲ 4% growthQ2 saw a medico-business decline after a strong Q1; the broader OTC and medico market was stagnant. Recent months have been much stronger, with high single-digit growth expected in Q3.
Pain Management▬ 1% growthFlattish in a challenging quarter.
Boroplus▼ Single-digit declineHit by price-sensitive mass consumers pulling back. The franchise is diversifying beyond antiseptic cream: lotion, soap, Boroplus Soft, and Aloe Vera Gel now contribute ~20-22% of total Boroplus sales.
Kesh King▼ Single-digit declineDecline tied to a promotional cycle: sales rise with consumer promotions and dip when they are withdrawn. Management is confident of a Q3 rebound and expects to end the year with positive growth.
Male Grooming (Fair and Handsome)▼ Single-digit declineBrand has reached stagnancy and needs a complete re-launch, which is now in the works.

Premium Bets & New Forays


International Business


Margins & Cost Structure

Mohan Goenka: "Second half margins, again Shirish I am saying that is not a concern honestly because raw material prices are still benign."

Competitive Landscape

Mohan Goenka: "I am more confident on the margin front. We can recover very significantly if the winter sets in well and there is good amount of rural recovery but in this difficult times I would say 7% is also a good top line number."

Guidance & Commitments

CommitmentSpecificsTimeline
Margin expansionAt least 200 bps expansion for the full yearFY24 exit
Top-line growthEnd the year in a similar range as H1 (~7%); high single-digit achievable if winter and rural recovery cooperateFY24 exit
Kesh KingReturn to growth in Q3; end the year on a positive growth noteQ3 FY24 / FY24 exit
Healthcare (Zandu)High single-digit growth in Q3 after a weak Q2Q3 FY24
CIS/RussiaBounce back to decent growth ratesQ3 and Q4 FY24
Male GroomingComplete re-launch of Fair and HandsomeNo date (in development)

Key Metrics

MetricQ2 FY24
Consolidated revenue₹865 cr, +6% YoY
Domestic net sales growth+4% YoY
Domestic volume growth~2% YoY
Gross margin70.1%, expanded 350 bps YoY
EBITDA₹234 cr, +20% YoY; margin at 27%, up 300 bps
H1 FY24 revenue growth~7% YoY
H1 FY24 EBITDA margin25.1%, up 180 bps YoY
H1 FY24 PAT₹316 cr, +23% YoY
International business growth+16% in constant currency, +12% in INR terms
Navratna and Dermi Cool range growth+12% YoY
Healthcare range growth+4% YoY
Pain management growth+1% YoY
Boroplus, male grooming, Kesh King rangeDeclined in single digits YoY
Helios and Brillare Sciences growth+63% YoY
Modern trade growth~17–18% YoY
E-commerce growth~50% YoY
E-commerce share of total business~13%
Modern trade share of total business11%
Chemist channel growth~20% YoY
Helios and Brillare combined revenue share~5% of total business
Boroplus extensions share of total Boroplus~20–22%
Interim dividend₹4 per share (400%) for FY2024
Promoter pledge level~15% of promoters' holding